Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · HALO · as of Mar 31, 2025
Ownership Breakdown
567
Institutional Holders
▲ 41 vs Q4
$7.75B
Total Inst. Value
▲ $1.89B vs Q4
118.61M
Shares Outstanding
freeFloat 98.85%
122.66M
13F Shares Held
▼ 1.16M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
HALO largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 17.09M | 13.87% | 13.87% | $1.09T | May 2, 2025 | ▼ 474.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 12.83M | 10.41% | 10.41% | $818.78B | May 9, 2025 | ▼ 450.2K |
STATE STREET CORP biological products, (no diagnostic substances) | 6.05M | 4.91% | 4.91% | $386.24B | May 15, 2025 | ▼ 1.13M |
INVESCO LTD. biological products, (no diagnostic substances) | 3.89M | 3.16% | 3.16% | $248.50B | May 12, 2025 | ▲ 1.52M |
SNYDER CAPITAL MANAGEMENT L P biological products, (no diagnostic substances) | 3.67M | 2.98% | 2.98% | $234.46B | May 15, 2025 | ▼ 494.2K |
ALLIANCEBERNSTEIN L.P. biological products, (no diagnostic substances) | 3.22M | 2.61% | 2.61% | $205.16B | May 15, 2025 | ▲ 146.7K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.17M | 2.57% | 2.57% | $202.27B | May 13, 2025 | ▲ 105.2K |
MACQUARIE GROUP LTD biological products, (no diagnostic substances) | 2.67M | 2.17% | 2.17% | $170.65B | Aug 14, 2025 | ▼ 231.2K |
JPMORGAN CHASE & CO biological products, (no diagnostic substances) | 2.47M | 2.01% | 2.01% | $157.92B | May 12, 2025 | ▲ 87.3K |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 2.31M | 1.88% | 1.88% | $147.66B | May 15, 2025 | ▼ 1.13M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
26
Increased
+5.23M shares2
New Positions
first time holders20
Decreased
−5.89M shares0
Sold Out
fully exitedNet shares change (top 50)
662.8K
+5.23M / −5.89M
Net new holders
+8
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
HALO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Torley Helen PRESIDENT AND CEO | Jun 1, 2026 | Sale | 1,610 | $66.39 | $106.9K | 786.2K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 400 | $66.37 | $26.5K | 777.4K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 1,500 | $67.67 | $101.5K | 775.9K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 2,000 | $68.74 | $137.5K | 773.9K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 1, 2026 | Sale | 12,989 | $67.41 | $875.6K | 773.2K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 2, 2026 | Sale | 16,600 | $66.31 | $1.10M | 771.2K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 2, 2026 | Sale | 3,400 | $66.75 | $226.9K | 767.8K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 1, 2026 | Sale | 5,401 | $68.35 | $369.1K | 767.8K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 6,100 | $69.69 | $425.1K | 767.8K | Form 4 ↗ |
Connaughton Bernadette director | Jun 1, 2026 | Sale | 1,625 | $66.21 | $107.6K | 43.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Halozyme Therapeutics, Inc. (HALO) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 1.15%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Halozyme Therapeutics, Inc. is BLACKROCK, INC., holding approximately 17.09 million shares — equal to 13.87% of outstanding shares — as of March 31, 2025.
A total of 567 institutional investors currently hold HALO stock, with a combined institutional value of approximately $7.75 billion as of the most recent 13F filing period.
Frequently asked questions
HALO ownershipHalozyme Therapeutics, Inc. (HALO) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 13.87% stake. Company insiders hold 1.15%. Data sourced from SEC Form 13F as of March 31, 2025.